Precision Medicine 2018: Assembling the Puzzle


Tuesday, June 26, 2018, 8:00am to 5:00pm


Joseph B. Martin Conference Center, 77 Ave. Louis Pasteur, Boston

Logo: Precision Medicine 2018

Patients continue to inspire and drive us to the leading edge of precision medicine.* Yet at perhaps the most exciting and promising focus of precision medicine—its application to oncology—precision seems to matter less than predicted even 5 years ago. On the one hand, therapies such as the immune modulating drugs have emerged that appear effective across dozens of different cancers, yet the discovery of “driver mutations” in individual cancers continues to influence drug development and clinical decision making. In this context, how can patients help drive optimal decision making and societal investments in effective treatment and prevention of cancer and other diseases?

Our keynote this year, Greg Simon, President of the Biden Cancer Initiative, is ideally placed to answer this question both from the perspective of his role in founding FasterCures, patient advocacy within the pharmaceutical industry, and as a cancer survivor. Science and clinical care do not exist in isolation, and thus our first panel will address the question, "How do we overcome the disconnect between Patients, Clinicians, Insurers & Educators?" The panel includes leading representatives from payors, investors, data-driven oncology companies and media.

The question of patient leadership in precision medicine will be further explored in our second panel featuring citizen scientists, professional scientists who are parents of children requiring precision medicine therapies, as well as representatives of precision medicine companies, such as Editas Medicine.

Our third panel, composed of luminaries in technology and data science, will explore how digital technologies can help us complement molecular characterizations for further precision and to implement new precision medicine clinical workflows.

In our closing keynote, we will hear from Gerry Cox as he describes how Editas Medicine brings extremely precise therapies to bear on the future of very individualized medicine.


Tuesday, June 26, 2018, 8:00 am – 5:00 pm ET


Joseph B. Martin Conference Center, 77 Ave. Louis Pasteur, Boston


REGISTER HERE via Eventbrite (conference is free but space is limited)


AC Hotel by Marriott Boston Cleveland Circle
395 Chestnut Hill Ave, Boston MA 02135
Click HERE to reserve, group rate $229/night.
Cut off date: May 15, 2018

The Inn at Longwood Medical
342 Longwood Avenue, Boston MA 02115
617-731-4700 (Group code: PREC2018)
Click HERE to reserve, group rate $219/night.
Cut off date: June 03, 2018



Contact us at



Conference Agenda

Time Topic & Speaker(s)
8:00–9:00am Continental Breakfast and Check-in
9:00–9:15am Welcome — Zak Kohane, Harvard Medical School
9:15–9:30am Opening Remarks — George Daley, Dean, Harvard Medical School
9:30–10:30am Opening Keynote — Greg Simon, President, Biden Cancer Initiative
10:30–10:45am BREAK
10:45am–12:00pm PANEL 1 — How do we overcome the disconnect between Patients, Clinicians, Insurers & Educators?
  • Amy Abernethy, Flatiron Health
  • Martha Bebinger, WBUR
  • Troyen Brennan, CVS
  • Lisa Suennen, GE Ventures
12:00–1:00pm LUNCH
1:00–2:15pm PANEL 2 — Is Patient Leadership Critical?
  • Gerald Cox, Editas Medicine
  • Jocelyn Duff, Cure CMT4J
  • Farhad Imam, Bill & Melinda Gates Foundation
  • Carol Martin, Harvard Catalyst
  • Stanley Nelson, UCLA
2:15–2:30pm BREAK
2:30–3:45pm PANEL 3 — How is Technology Empowering Precision Medicine?
  • Andrew Beam, Harvard Medical School
  • Keith Dunleavy, Inovalon
  • Dina Katabi, MIT
  • Calum MacRae, Brigham & Women’s Hospital
  • Paul Varghese, Verily
3:45–4:00pm BREAK
4:00–4:45pm Closing Keynote — Jeremy Levin, CEO, Ovid Therapeutics
4:45–5:00pm Closing Remarks — Zak Kohane, Harvard Medical School


*What do we mean by “precision medicine”? From the perspective of one of the members of the National Academy of Sciences committee that wrote the report, we mean taking an explicit multidimensional view of patients: not just one data modality such as genomics or environmental exposure. We argue that this perspective allows for more precise matching of humans to disease states (diagnosis), future disease states (prognosis) and appropriate therapies.

Conference co-sponsored by DBMI, PIC-SURE, Amazon Web Services, Datavant, Novartis, and Verily.

 | Return to top |